Completed PHASE2 INTERVENTIONAL 1-arm NCT00796757

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Sponsor: Hoffmann-La Roche

Conditions Renal Cell Cancer

Interventions bevacizumab [Avastin] interferon alfa-2a

Updated 6 times since 2017 Last updated: May 22, 2015 Started: Dec 31, 2008 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00796757, this PHASE2 trial focuses on Renal Cell Cancer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Amstelveen, Netherlands , Arnsberg, Germany , Augsburg, Germany , Barnaul, Russia , Berlin, Germany , Cambridge, United Kingdom , Cardiff, United Kingdom , Eindhoven, Netherlands , Eskilstuna, Sweden and 35 more locations